# Varex Imaging Corporation (VREX) Investor Outlook: 21.55% Potential Upside and Robust Revenue Growth

- Link: https://www.directorstalkinterviews.com/varex-imaging-corporation-vrex-investor-outlook-21-55-potential-upside-and-robust-revenue-growth/4121236070
- Published: 2026-01-22T11:19:53+00:00
- Author: Madison Wilson

For investors eyeing opportunities in the healthcare sector, Varex Imaging Corporation(
NASDAQ: VREX) presents an intriguing proposition. With a market capitalization of
$593.16 million, Varex operates in the medical devices industry, specializing in
X-ray imaging components. The company’s diverse portfolio spans both the medical
and industrial sectors, servicing a wide array of applications from CT scans to 
cargo inspections.

Currently trading at $14.15, Varex Imaging has experienced a notable range over 
the past year, with its stock price swinging between $6.88 and $15.20. This volatility
is not uncommon in the medical devices industry, particularly for a company as specialized
as Varex, which caters to both niche medical and industrial markets.

A key figure that stands out is the company’s revenue growth, which has climbed 
11.3%. This is significant for a company in the healthcare sector, where innovation
and consistent demand for diagnostic solutions often drive growth. Despite this 
positive revenue trajectory, Varex is yet to achieve profitability, as reflected
in its negative earnings per share (EPS) of -$1.70 and a concerning return on equity(
ROE) of -13.58%. These figures suggest that while the company is expanding its top
line, it continues to grapple with operational efficiency and profitability challenges.

Investors looking for value metrics might find Varex’s current valuation a mixed
bag. The absence of a trailing P/E ratio points to the challenges of valuing a company
that is not yet profitable. However, the forward P/E of 14.70 indicates that analysts
anticipate improvements in earnings, potentially driven by operational efficiencies
or market expansion.

Analyst sentiment towards Varex is predominantly optimistic. Out of the analysts
covering the stock, four have issued buy ratings, and one a hold, with no sell recommendations.
The average target price stands at $17.20, suggesting a potential upside of 21.55%
from the current price level. This optimistic outlook is bolstered by the company’s
technical indicators, with the stock trading above its 50-day and 200-day moving
averages, hinting at a bullish trend.

Despite the promising aspects, investors should be cautious of the company’s dividend
policy, as Varex does not currently offer a dividend. This aligns with its zero 
payout ratio, highlighting its focus on reinvesting earnings to fuel further growth
and innovation rather than distributing profits to shareholders.

Varex’s global footprint spans North America, Latin America, Europe, the Middle 
East, India, Africa, Asia, and Australia, reflecting its strategic positioning to
tap into diverse markets. This geographical diversification could serve as a buffer
against localized economic downturns, offering some stability in revenue streams.

Overall, Varex Imaging Corporation presents a compelling case for growth-focused
investors willing to accept the inherent risks of investing in a company still navigating
its path to profitability. With a strong foothold in the medical imaging and industrial
inspection markets, Varex is positioned to leverage its innovative product offerings
and extensive international presence. However, potential investors should remain
mindful of the operational and market risks that could impact future performance.

Share on:
